Lundbeck

Name

Lundbeck

Legal name

H. Lundbeck A/S

Website

https://lundbeck.com

Company type

Public

Founded year

1915

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Central Nervous System Pharmaceuticals

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Headache & Migraine Medicine (HLAKAIAE), Autonomic Disorders (Dysautonomia) (HLAKAIAN), Movement Disorders (Parkinson’s, Tremor, Dystonia) (HLAKAIAC), Endocrine Hypertension & Neuroendocrine Disorders (HLAKADAN)

Keywords

• Central nervous system pharmaceuticals
• Neurological disorder treatments
• Migraine preventive therapies
• Rare epilepsy medications
• Psychiatric disorder drugs

Headquarters

HQ city

Valby

HQ country

Denmark

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical drug sales: Revenue generated from sale of prescription pharmaceutical products for neurological and psychiatric disorders. Products include Vyepti (eptinezumab) for migraine prevention, Rexulti (brexpiprazole) for schizophrenia and depression, and other CNS treatments. Revenue from both established products and newly launched drugs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

H. Lundbeck A/S is a global pharmaceutical company that researches, develops, manufactures, and commercializes prescription drugs for psychiatric and neurological (CNS) disorders. Its marketed portfolio includes Vyepti (eptinezumab) for migraine prevention, Rexulti (brexpiprazole) for schizophrenia and major depressive disorder, Abilify Asimtufii for schizophrenia and bipolar I, Trintellix (vortioxetine), and Cipralex/Lexapro (escitalopram), while its investigational pipeline targets rare epilepsies, Parkinson's disease, multiple system atrophy, Cushing's disease, and thyroid eye disease through novel mechanisms such as anti-PACAP, anti-ACTH, 5-HT2C agonism, anti-alpha-synuclein, and CD40L blockade.

Product overview

Lundbeck is a Danish pharmaceutical company focused on brain disorders, offering a portfolio of approved and investigational treatments spanning multiple therapeutic areas. Approved products include Vyepti (eptinezumab), a CGRP inhibitor for migraine prevention, alongside Rexulti, Abilify Asimtufii, Trintellix, and Cipralex/Lexapro for psychiatric conditions. The investigational pipeline includes bocunebart (anti-PACAP antibody for migraine), bexicaserin (5-HT2C agonist for rare epilepsies acquired from Longboard), amlenetug (anti-alpha-synuclein for MSA with Genmab partnership), asedebart (anti-ACTH for Cushing's disease), Lu AF28996 (D1/D2 agonist for Parkinson's), and Lu AG22515 (CD40L blocker for thyroid eye disease). The company is expanding from its neuroscience heritage into neuroendocrine and neuroimmunology indications, with strategic focus on AI-driven drug discovery through partnerships with Cradle AI, OpenAI, and Iambic Therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• Vyepti (eptinezumab): FDA-approved monoclonal antibody for migraine prevention targeting CGRP pathway
• bocunebart (Lu AG09222)
• bexicaserin
• asedebart (Lu AG13909)
• amlenetug
• Lu AF28996

Products and services

• Vyepti (eptinezumab) FDA-approved monoclonal antibody CGRP inhibitor administered via quarterly intravenous infusion for the preventive treatment of migraine in adults. Marketed in the US, Europe, and Asia (including South Korea), supported by Phase 3 SUNRISE and Phase IV RESOLUTION trial data. Reached DKK 4.48 billion (~$711M) in 2025 sales with 59% YoY growth.
• Rexulti (brexpiprazole) Atypical antipsychotic co-developed with Otsuka for the treatment of schizophrenia and as adjunctive therapy for major depressive disorder. Generated approximately DKK 6.21 billion (~$973M) in 2025 sales, up 23% YoY, and DKK 4.7B ($737M) in the first nine months of 2025. Faces US patent exclusivity expiration at end of 2028.
• Abilify Asimtufii (aripipiprazole) Once-every-two-months long-acting injectable aripiprazole formulation for maintenance therapy of schizophrenia and bipolar I disorder. Marketed in Canada with broad public reimbursement and commercially distributed through Lundbeck Canada Inc.
• Trintellix (vortioxetine)
• Cipralex/Lexapro (escitalopram)

Quantifiable outcome

• Bexicaserin showed sustained seizure reduction of 60.2% at 18 months and 53.7% at 24 months in DEE patients
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• CradlecoreTechnology or Integration · 10 June 2026Multi-year AI partnership to co-develop novel monoclonal antibody therapeutics for central nervous system disorders using closed-loop generative protein engineering approach. Integrates Cradle's AI-driven protein design platform with Lundbeck's CNS domain expertise for iterative antibody candidate design, testing, and refinement. Industry benchmarks suggest this paradigm can reduce antibody discovery timelines by 5-10 times compared to traditional methods.
• Zuellig PharmacoreChannel Partner/ Reseller/ Distributor · 16 December 2025Expanded partnership with Zuellig Pharma to serve as agency partner for commercializing Lundbeck's neuro-psychiatric health products including Lexapro, Brintellix, and Cipralex across Indonesia, Malaysia, Philippines, Singapore, and Taiwan. Builds on existing distribution relationship with end-to-end commercialization services.
• OpenAIcoreTechnology or Integration · 27 October 2025Strategic partnership to deploy enterprise-grade AI tools including ChatGPT Enterprise across Lundbeck's operations, focusing on neuroscience research and therapy development. Initiative aims to accelerate research, streamline analysis, and boost efficiency across the global workforce, following successful pilots.
• Contera PharmacoreStrategic or Co-development Partner · 20 October 2025Research collaboration to advance RNA-targeting medicines for serious neurological conditions. Partnership aims to accelerate discovery of oligonucleotide-based treatments by leveraging combined expertise and proprietary platforms.
• Genmab A/ScoreStrategic or Co-development PartnerJoint licensing agreement for development of amlenetug, a monoclonal antibody targeting alpha-synuclein for multiple system atrophy (MSA). Amlenetug has received Orphan Drug Designation in EU, Japan, and US, as well as Fast Track designation in US and SAKIGAKE designation in Japan. Lundbeck completed Phase III MASCOT trial enrollment ahead of schedule.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Otsuka Pharmaceutical: Co-development partner with Lundbeck on Rexulti (brexpiprazole) for schizophrenia and MDD. Both companies share CNS focus, with Otsuka also active in psychiatry and rare-disease neurology, making it the closest direct collaboration peer in Lundbeck's core franchise.
• Jazz Pharmaceuticals: Specialty CNS pharmaceutical company with a similar commercial model targeting neurology and psychiatry via specialty sales forces. Jazz's Xywav/Epidiolex franchises and rare neurology focus closely mirror Lundbeck's neuro-rare and migraine strategies.
• UCB: Belgian specialty pharma with a strong CNS and rare-disease focus, including epilepsy (Vimpat, Keppra) and immunology. UCB's pipeline in developmental epilepsies and migraine makes it a directly comparable CNS specialty peer with overlapping patient populations.
• Neurocrine Biosciences: US CNS specialty pharma focused on neurology and psychiatry, with commercial products in movement disorders (Ingrezza) and a pipeline spanning schizophrenia, epilepsy, and rare CNS indications. Closely aligned strategic profile to Lundbeck's neuro-rare and psychiatry focus.

Broad incumbents

• Biogen: Larger established biopharmaceutical company with a strong neuroscience heritage and rare neurological disease focus (Spinraza, SMA; recently launched Reata, Skyclarys). Comparable neuroscience research infrastructure and rare neurology commercial franchise make it a broad incumbent peer.
• AbbVie: Diversified major pharma with a major CNS franchise (Vraylar for schizophrenia/MDD, Botox for chronic migraine) and a long history in neurology and psychiatry. As a broader incumbent with overlapping products in migraine and psychiatry, it represents a larger competitor in Lundbeck's core categories.
• Pfizer: Global biopharmaceutical major with broad CNS and migraine exposure (Nurtec ODT, acquired via Biohaven) and active rare-disease strategy. As a large incumbent with overlapping migraine and rare-disease ambitions, Pfizer is a broad competitive peer.

Emerging players

• Axsome Therapeutics: Emerging CNS-focused biopharma with approved products in depression (Auvelity) and migraine (Symbravo). Axsome is a smaller, faster-growing specialty player in overlapping therapeutic categories, making it a comparable emerging competitor in migraine and depression.
• Sage Therapeutics: CNS-focused biopharma developing treatments for depression, epilepsy, and other neurological conditions. The company's Zurzuvae (postpartum depression) and pipeline overlap with Lundbeck's psychiatry and rare epilepsy focus make it a relevant emerging peer.

Regional players

• Recordati: European specialty pharma with established CNS franchises across rare diseases and neurology, primarily serving EU markets. Comparable specialty-pharma business model and European commercial footprint make it a regional peer in Lundbeck's home market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/lundbeck
• LinkedInlinkedin.com/company/lundbeck

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lundbeck